Effects on syngeneic tumors of F1 lymphocytes sensitized in vitro by parental stimulator cells. 1985

I J Havelaar, and C S McCullough, and P H Sugarbaker

F1 lymphocytes stimulated in vitro by parental cells were evaluated for cytotoxicity against semisyngeneic tumors and lymphoblasts. B6AF1 (H-2a,b) spleen cells were placed in culture with C57BL/6 (H-2b) or B10.A (H-2a) cells and 6 days later were assayed for cell-mediated cytotoxicity in vitro; also subcutaneous, intraperitoneal, and intrapulmonary tumor neutralization experiments were performed. F1 lymphocytes sensitized by parental cells showed high levels of cytotoxicity to the tumor cells of the parental haplotype but no lysis of parental blastoid cells. Tumor cells from irrelevant haplotypes were also lysed. The cells mediating in this type of killing were characterized phenotypically as Thy-1.2- and Lyt-2.2-positive. In a subcutaneous tumor neutralization test (Winn assay), marked suppression of EL-4 lymphoma (H-2b) and B16 melanoma (H-2b) was observed. Likewise, tumor control was seen in an intraperitoneal tumor model. These studies show that F1 versus parental sensitization can be used to lyse tumor in vitro and in vivo and should be explored as an immunotherapeutic tool.

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002860 Chromium Radioisotopes Unstable isotopes of chromium that decay or disintegrate emitting radiation. Cr atoms with atomic weights of 46-49, 51, 55, and 56 are radioactive chromium isotopes. Radioisotopes, Chromium
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic

Related Publications

I J Havelaar, and C S McCullough, and P H Sugarbaker
December 1975, Israel journal of medical sciences,
I J Havelaar, and C S McCullough, and P H Sugarbaker
January 1980, The Journal of experimental medicine,
I J Havelaar, and C S McCullough, and P H Sugarbaker
November 1980, Journal of immunology (Baltimore, Md. : 1950),
I J Havelaar, and C S McCullough, and P H Sugarbaker
September 1976, Transplantation proceedings,
I J Havelaar, and C S McCullough, and P H Sugarbaker
July 1981, Cancer research,
I J Havelaar, and C S McCullough, and P H Sugarbaker
January 1976, Annals of the New York Academy of Sciences,
I J Havelaar, and C S McCullough, and P H Sugarbaker
April 1978, Journal of immunology (Baltimore, Md. : 1950),
I J Havelaar, and C S McCullough, and P H Sugarbaker
February 1979, Journal of immunology (Baltimore, Md. : 1950),
I J Havelaar, and C S McCullough, and P H Sugarbaker
January 1985, Eksperimental'naia onkologiia,
I J Havelaar, and C S McCullough, and P H Sugarbaker
January 1972, International journal of cancer,
Copied contents to your clipboard!